358 Results for "

EGF-R kinases

" in MedChemExpress (MCE) Product Catalog:
Products (358)

358 Results for "EGF-R kinases" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-18963
CAS No.: 125697-92-9
Synonyms: RG-14355
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15769
CAS No.: 211555-08-7
Purity:  99.84%
Synonyms: Janex 3
Target:  

RET VEGFR EGFR

Research Areas:  

Cancer

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109189
CAS No.: 1835667-12-3
Purity:  99.62%
Synonyms: BPI-7711
Target:  

EGFR

Research Areas:  

Cancer

Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100499
CAS No.: 133550-49-9
Purity:  ≥98.0%
Synonyms: Tyrphostin B66; AG 528
Target:  

EGFR

Research Areas:  

Cancer

Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC50s of 4.9 μM for epidermal growth factor receptors (EGFR) and 2.1 μM for ErbB2 . Tyrphostin AG 528 is also an anticancer agent .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12972
CAS No.: 1776112-90-3
Purity:  99.34%
Synonyms: PF-06747775
Target:  

EGFR

Research Areas:  

Cancer

Mavelertinib is a selective, orally available and irreversible EGFR tyrosine kinase inhibitor (EGFR TKI), with IC50s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively. Mavelertinib can be used for the research of non-small-cell lung cancer (NSCLC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-118532
CAS No.: 122520-79-0
Purity:  99.70%
Synonyms: AG30
Target:  

EGFR

Research Areas:  

Cancer

Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-157229
CAS No.: 2765525-82-2
Purity:  98.25%
Target:  

EGFR ERK

Research Areas:  

Cancer

STX-721 is an orally active, irreversible, covalent EGFR exon 20 insertion (ex20ins) inhibitor that selectively targets ex20ins-mutant dynamic protein states. STX-721 potently inhibits the kinase activity of EGFR ex20ins mutants (NPG, ASV, SVD). STX-721 inhibits phosphorylation of EGFR (pEGFR Y1068) and downstream ERK (pERK Thr202/Tyr204), and suppresses proliferation of ex20ins-mutant Ba/F3 cells and human NSCLC cell lines (NCI-H2073 ASV KI, CUTO-14 ASV). STX-721 induces tumor regression in EGFR ex20ins-mutant PDX/CDX models. STX-721 can be used for the study of non-small cell lung cancer (NSCLC) harboring EGFR or HER2 ex20ins mutations .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107459
CAS No.: 134036-52-5
Purity:  99.71%
Synonyms: (E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42
Target:  

EGFR STAT JAK

Research Areas:  

Cancer

(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-116437
CAS No.: 1275595-86-2
Purity:  99.83%
Target:  

EGFR

Research Areas:  

Cancer

Selatinib is an orally active EGFR and HER2 tyrosine kinase inhibitor with IC50 values of 13.0 nM and 8.5 nM, respectively. Selatinib undergoes oxidative metabolism in vivo to produce Lapatinib (HY-50898). Selatinib inhibits the growth of breast, gastric and ovarian tumors. Selatinib can be used in research related to gastric cancer, breast cancer and ovarian cancer .
loading...
    loading...
Cat. No.: HY-19815
CAS No.: 1660963-42-7
Synonyms: CK-101; RX518
Target:  

EGFR

Research Areas:  

Cancer

Olafertinib (CK-101) is an orally available, third generation and irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Olafertinib selectively inhibits both EGFR-TKI-sensitizing and resistance mutations with minimal activity on wild-type EGFR. Olafertinib can be used in research for non-small cell lung cancer (NSCLC) with EGFR mutations and other advanced malignancies .
loading...
    loading...
Cat. No.: HY-59219
CAS No.: 411235-57-9
Cyclopropylboronic acid is an intermediate. Cyclopropylboronic acid can be used to synthesize EGFR kinase inhibitor (Compound 25). Compound 25 has antiproliferative effects on EGFR mutant (EGFR Δ19del/T790M/C797S) cells. Cyclopropylboronic acid can be used in lung cancer research .
loading...
    loading...
Cat. No.: HY-128862
CAS No.: 2267329-76-8
Purity:  99.76%
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 can be used for the research of various cancers .
loading...
    loading...
Cat. No.: HY-136430
CAS No.: 2305154-31-6
Purity:  99.76%
Synonyms: JGK037
Target:  

EGFR

Research Areas:  

Cancer

JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC50 values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively .
loading...
    loading...
Cat. No.: HY-P2503
CAS No.: 945830-38-6
Target:  

EGFR

Research Areas:  

Cancer

EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.
loading...
    loading...
Cat. No.: HY-17499
CAS No.: 879127-07-8
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

EGFR-IN-12 is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective EGFR inhibitor with an IC50of 21 nM. EGFR-IN-12 also inhibits mutant EGFR L858R and EGFR L861Q with IC50s of 63 nM and 4 nM, respectively. EGFR-IN-12 displays strong selectivity for EGFR over HER4 (IC50 = 7640 nM) and a panel of 55 other kinases. EGFR-IN-12 induces cells apoptosis and has antitumor activity .
loading...
    loading...
Cat. No.: HY-108484
CAS No.: 5334-30-5
Purity:  98.78%
Target:  

EGFR

Research Areas:  

Cancer

PP 3 (Compound 3) is an EGFR tyrosine kinase inhibitor with an IC50 of 2.7 μM .
loading...
    loading...
Cat. No.: HY-101006
CAS No.: 63177-57-1
Purity:  99.70%
Target:  

EGFR

Research Areas:  

Cancer

Methyl 2,5-dihydroxycinnamate is an erbstatin analog and a stable, potent inhibitor of EGFR kinase activity .
loading...
    loading...
Cat. No.: HY-101820
CAS No.: 944258-89-3
Purity:  99.39%
Target:  

EGFR

Research Areas:  

Cancer

Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities .
loading...
    loading...
Cat. No.: HY-112412
CAS No.: 205254-94-0
Purity:  99.85%
Target:  

PDGFR

Research Areas:  

Neurological Disease

PDGFR Tyrosine kinase-IN-1, a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine kinase-IN-1 can be used for the research of amyotrophic lateral sclerosis .
loading...
    loading...
Cat. No.: HY-152852
CAS No.: 1639014-72-4
Purity:  99.40%
Synonyms: Mifanertinib
Target:  

EGFR

Research Areas:  

Cancer

Mefatinib free base (Mifanertinib) is an orally active EGFR and HER2 kinase inhibitor with IC50 values of 0.4 nM and 11.7 nM, respectively. Mefatinib free base inhibits tumor growth in mouse models of lung cancer xenografts that overexpress EGFR/HER2, carry EGFR mutations, or carry Erlotinib (HY-50896)-resistant EGFR double mutations. Mefatinib free base can be used for the research of advanced EGFR-mutant non-small cell lung cancer .
loading...
    loading...